Welcome to our dedicated page for Pasithea Therapeutics news (Ticker: ktta), a resource for investors and traders seeking the latest updates and insights on Pasithea Therapeutics stock.
Pasithea Therapeutics Corp (NASDAQ: KTTA) is a clinical-stage biotechnology company advancing novel therapies for central nervous system disorders and genetic conditions. This dedicated news hub provides investors and industry observers with timely updates on the company's scientific progress, regulatory milestones, and strategic initiatives.
Our curated collection offers comprehensive tracking of KTTA's developments including clinical trial updates for its lead candidate PAS-004, research collaborations, and advancements in treating conditions like Neurofibromatosis Type 1 and ALS. The content is organized to help stakeholders efficiently monitor the company's progress in neuroscience innovation and drug development.
Key updates cover regulatory filings, partnership announcements, peer-reviewed research publications, and clinical trial results. All content maintains strict editorial standards to ensure accuracy and relevance for both professional investors and those new to biotech equities.
Bookmark this page for centralized access to verified information about Pasithea's therapeutic pipeline, including its work on MEK inhibitors and translational medicine approaches. Check back regularly for essential updates that could impact long-term research trajectories and market positioning.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) announced that CEO Dr. Tiago Reis Marques will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The presentation is scheduled for September 12, 2022, at 7:00 AM ET. Attendees can request virtual one-on-one meetings through H.C. Wainwright. A pre-recorded presentation will also be available on the Company’s website. Pasithea focuses on researching treatments for psychiatric and neurological disorders, including IV ketamine infusions for patients in clinical and home settings.
Camac Partners, LLC, along with affiliates of Concord Investment Partners Ltd. and Leonite Capital LLC, have gained support from fellow stockholders of Pasithea Therapeutics Corp. (KTTA) to call a Special Meeting. The Investor Group is pushing for the removal of all current directors to enhance corporate governance and improve capital allocation. The group is prepared to petition the Delaware Court of Chancery if necessary, emphasizing the urgency for change and a commitment to value creation for shareholders.
The Investor Group comprising Camac Partners, Concord Investment Partners, and Leonite Capital, significant stockholders of Pasithea Therapeutics Corp. (NASDAQ: KTTA), announced their intention to call a Special Meeting of Stockholders. Their motivation is a lack of confidence in the current Board of Directors, which they believe is mismanaging investor capital. The group urges fellow shareholders to support their initiative by returning proxy cards promptly, emphasizing that every vote is crucial for their efforts to succeed.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) will present preclinical results of its DNA vaccine, PAS002, targeting multiple sclerosis at the conference 'From Laboratory to Clinic: Medicine after COVID' on August 30, 2022, at Trinity College, Oxford University. The conference, established in 1984, unites researchers to share advancements in immunology and molecular medicine. CEO Dr. Tiago Reis Marques expressed optimism about the findings contributing to new treatments for neurological disorders. The keynote will be delivered by Professor Lawrence Steinman, along with other leading experts in the field.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) announced positive results from a preclinical study of its tolerizing vaccine, PAS002, targeting multiple sclerosis (MS). The study involved a mouse model of relapsing-remitting experimental autoimmune encephalomyelitis, demonstrating significant efficacy in reducing disease severity and relapse rates (p<0.001). Key findings include delays in paralysis onset and a 50% prevention rate of disease. PAS002 leverages the GlialCAM protein, which also relates to monkeypox virus, potentially expanding its therapeutic applications. The company has filed a provisional patent and aims for rapid development.
Camac Partners, LLC and affiliates have called for a Special Meeting of stockholders at Pasithea Therapeutics (NASDAQ: KTTA) to remove the current Board of Directors. They cite a loss of over 80% in stock value since its IPO, attributing this decline to dilutive acquisitions and insider transactions that favor the Board at the expense of shareholders. The stock has plummeted from
Pasithea Therapeutics Corp. (Nasdaq: KTTA) has filed a consent revocation statement in response to a solicitation by the Camac Group to call a Special Meeting of Stockholders. The Board unanimously recommends that stockholders reject this effort, viewing it as a self-serving attempt that could undermine the Company's progress and potential value. Pasithea, focused on groundbreaking therapies for psychiatric and neurological disorders, aims to protect stockholder interests and has raised over $55 million since its IPO in September 2021. The company warns that a successful takeover could lead to cash depletion and hinder its development efforts.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) announced a AUD $1 million (U.S. $694,000) grant from FightMND for drug development related to ALS treatments. This funding, part of Pasithea's acquisition of Alpha-5 Integrin, LLC, will support research into monoclonal antibodies targeting the alpha-5/beta-1 integrin. These candidates are aimed at improving outcomes for ALS patients, a disease without a known cure. The grant provides non-dilutive funding that will expedite preclinical testing in mouse models.
The Investor Group, comprising Camac Partners, Concord Investment Partners, and Leonite Capital, has expressed strong opposition to Pasithea Therapeutics Corp.'s recent acquisition of Alpha-5 integrin, which they deem dilutive and reactionary. They highlight a significant decline in Pasithea's stock price, down 79% since its IPO, and a 60% discount to cash on hand. The group intends to withhold votes for the current directors at the upcoming annual meeting and will seek a special meeting to remove the board, citing poor governance and a disregard for shareholders.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) has announced its acquisition of Alpha-5 integrin, LLC, for an enterprise value of $3.75 million, consisting of 3.26 million shares of Pasithea common stock and 1 million warrants. Alpha-5 is developing a novel monoclonal antibody for treating amyotrophic lateral sclerosis (ALS) and other neuroinflammatory disorders. The acquisition enhances Pasithea's pipeline and includes proprietary technology and a skilled scientific team. A webcast will be held on June 22, 2022, to discuss further details.
